Metrochem API Private Limited Metrochem API Private Limited

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$77.4 million","upfrontCash":"$4.7 million","newsHeadline":"Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Announces VCN Biosciences\u2019 VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","amount":"$4.7 million","upfrontCash":"Undisclosed","newsHeadline":"Synthetic Biologics Completes Acquisition of VCN Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by VCN Biosciences

    Menu

    VCN Biosciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              VCN Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference

              Details:

              VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma.

              Lead Product(s): VCN-01,Gemcitabine,Paclitaxel

              Therapeutic Area: Oncology Product Name: VCN-01

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Theriva Biologics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              VCN Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Synthetic Biologics Completes Acquisition of VCN Biosciences

              Details:

              The acquisition transforms Synthetic Biologics’ pipeline with the addition of VCN's lead clinical-stage drug candidate, VCN-01, as well as preclinical stage VCN-11, both of which are next-generation OVs in development for the treatment of cancers with high unmet need.

              Lead Product(s): VCN-01,Gemcitabine,Paclitaxel

              Therapeutic Area: Oncology Product Name: VCN-01

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Theriva Biologics

              Deal Size: $4.7 million Upfront Cash: Undisclosed

              Deal Type: Acquisition March 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              VCN Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Synthetic Biologics Announces VCN Biosciences’ VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

              Details:

              VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma.

              Lead Product(s): VCN-01,Gemcitabine,Paclitaxel

              Therapeutic Area: Oncology Product Name: VCN-01

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Theriva Biologics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              VCN Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumo...

              Details:

              VCN has the rights to four exclusive patents for proprietary technologies, including VCN-01, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional patents pending.

              Lead Product(s): VCN-01,Gemcitabine,Paclitaxel

              Therapeutic Area: Oncology Product Name: VCN-01

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Grifols International

              Deal Size: $77.4 million Upfront Cash: $4.7 million

              Deal Type: Acquisition December 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Veranova: A CDMO that manages complexity with confidence.
              Axplora- The partner of choice for complex APIs.
              Post Enquiry
              POST ENQUIRY